{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:57Z","timestamp":1753891077894,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Radical cystectomy (RC) combined with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive bladder cancer (MIBC). For metastatic MIBC patients, platinum-based chemotherapy remains the first choice treatment. However, approximately 50% of patients with metastatic MIBC are ineligible for platinum-based adjuvant chemotherapy because of impaired renal function. In programmed death ligand 1 (PD-L1)-positive patients who cannot tolerate platinum-based chemotherapy, immunotherapy is recommended. Thus, a major shift is taking place in the treatment of patients with metastatic MIBC. There is currently much interest in the use of chemotherapy combined with immunotherapy and maintenance immunotherapy for the treatment of metastatic MIBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>One patient with metastatic MIBC exhibited promising progression-free survival (PFS) and safety and had good renal function after RC and toripalimab combined with chemotherapy plus toripalimab maintenance therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RC plus adjuvant therapy (toripalimab combined with chemotherapy) plus toripalimab maintenance therapy is a potential treatment option for metastatic MIBC patients who want to prolong their life. Moreover, a high tumor proportion score (TPS) of PD-L1 expression as well as CDKN2A and TP53 mutation levels may predict immunotherapy efficacy and patient prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1485744","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:48:53Z","timestamp":1734504533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Wei","family":"Ning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengkang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2020.99.01","article-title":"Bladder preservation in muscle-invasive bladder cancer: a comprehensive review","volume":"46","author":"Hamad","year":"2020","journal-title":"Int Braz J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of life after radical cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.01.003","article-title":"Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: A systematic review","volume":"4","author":"de Kruijff","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41467-021-25103-7","article-title":"An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer","volume":"12","author":"Gouin","year":"2021","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02019-6","article-title":"CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2022.2118606","article-title":"Immunotherapy for bladder cancer: latest advances and ongoing clinical trials","volume":"51","author":"Ward Grados","year":"2022","journal-title":"Immunol Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-017-0549-7","article-title":"Immune checkpoint blockade: the new frontier in cancer treatment","volume":"13","author":"Clarke","year":"2018","journal-title":"Target Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949567","article-title":"Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases","volume":"9","author":"Mao","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12894-022-01083-8","article-title":"Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study","volume":"22","author":"Ren","year":"2022","journal-title":"BMC Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.3390\/ijms22062800","article-title":"Improving anti-PD-1\/PD-L1 therapy for localized bladder cancer","volume":"22","author":"de Jong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment","volume":"35","author":"Zhou","year":"2017","journal-title":"Urol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1822743","article-title":"Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer","volume":"20","author":"Moussa","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"734.e1","DOI":"10.1016\/j.urolonc.2021.06.001","article-title":"PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue","volume":"39","author":"Schulz","year":"2021","journal-title":"Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205216","article-title":"p16","volume":"71","author":"Serra","year":"2018","journal-title":"J Clin Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.808208","article-title":"Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm Sin B"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1485744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:48:55Z","timestamp":1734504535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1485744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2024.1485744"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1485744","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1485744"}}